SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health. Consensus Development Panel on Impotence. JAMA 1993; 280: 083090.
  • 2
    Levine SB, Althof SE, Turner LA, et al. Side-effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 5457.
  • 3
    Eardley I, Brook J, Yates PK, Wulff MB, Boolell M. Sildenafil (Viagra®), a novel oral treatment with rapid onset of action for penile erectile dysfunction. Abstract. Br J Urol 1997; 79(Suppl 4): 66.
  • 4
    Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 4752.
  • 5
    Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C20C.
  • 6
    Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 13971404.
  • 7
    Dinsmore W, Hodges M, Hargreaves C, Osterloh I, Smith M, Rosen R. Sildenafil citrate (Viagra®) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800805.DOI: 10.1016/s0090-4295(98)00586-x
  • 8
    Cooper JDH, Muirhead DC, Taylor JE, Baker PR. Development of an assay for the simultaneous determination of sildenafil (Viagra®) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 701: 8795.
  • 9
    Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297310.DOI: 10.1080/004982599238687
  • 10
    Muirhead GJ, Allen MJ, James GC, et al. Pharmacokinetics of sildenafil (Viagra®), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br J Clin Pharmacol 1996; 42: 268P.
  • 11
    Sjöqvist Borgå O, Dahl M-L, Orme MLE. Fundamentals of clinical pharmacology. In: Avery's Drug Treatment 4th edn, eds. SpeightTM, HolfordNHG. Auckland, New Zealand. Adis International Limited, 1997; 273.
  • 12
    Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51: 239248.DOI: 10.1046/j.1365-2125.2001.00318.x
  • 13
    Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra®) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 6974.
  • 14
    Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra®) efficacy and safety. Int J Clin Pract 2001; 55: 115128.
  • 15
    Laties A, Ellis P, Koppiker N, Patat A, Stuckey B. Visual function testing in patients and healthy volunteers receiving Viagra®. Ophthalmic Res 1998; 30(Suppl 1): 177.